Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05809557 · ClinicalTrials.gov registry record · NA
EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity
A NA study of Metastatic Solid Tumor and Oncology, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05809557 is a NA study of Metastatic Solid Tumor and Oncology that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 34 participants, below the 192-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05809557, a NA study of Metastatic Solid Tumor and Oncology, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will formally test the quality improvement intervention of an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity.
Conditions Studied
Interventions
- OTHER Chemotherapy toxicity tool
- OTHER Oncology Consultation
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2024-01-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05809557
The ClinicalTrials.gov registry entry for NCT05809557 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (82% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy toxicity tool is the first listed.
NCT05809557 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05809557 about?
NCT05809557 is a clinical study titled "EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity". This study will formally test the quality improvement intervention of an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity.
What is the current status of trial NCT05809557?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2023-01-09. Estimated completion is 2024-01-09.
What conditions does trial NCT05809557 study?
This clinical trial studies the following conditions: Metastatic Solid Tumor, Oncology, Chemotherapeutic Toxicity.
What interventions are being tested in trial NCT05809557?
The interventions under investigation include: Chemotherapy toxicity tool (OTHER), Oncology Consultation (OTHER).
Who is sponsoring clinical trial NCT05809557?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05809557 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RECRUITING · Phase 1
-
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.